Assertio Holdings, Inc.

The company operates as a pharmaceutical company with comprehensive commercial capabilities, focusing on marketing differentiated products primarily in the oncology market, designed to address patients' needs. Its product portfolio has been built through the acquisition or licensing of approved products ¹.

The company's core business model revolves around generating revenue through product sales and royalty income. Its primary customer segments are three large, national wholesale distributors, which represent the majority of its revenues from net product sales ². The company sells its products to these wholesalers, who then sell to hospitals, outpatient clinics, and pharmacies. The company maintains relationships with these entities and healthcare professionals through its sales force to generate demand for its products ³.

The company's primary marketed products include ROLVEDON, Sympazan, INDOCIN Suppositories and Oral Suspension, SPRIX Nasal Spray, and CAMBIA. ROLVEDON (eflapegrastim-xnst) injection is a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients receiving anti-cancer drugs ⁴. Sympazan (clobazam) oral film is a benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients aged two years or older ⁵. INDOCIN (indomethacin) Suppositories and Oral Suspension are NSAIDs indicated for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis ⁶. SPRIX (ketorolac tromethamine) Nasal Spray is a prescription NSAID indicated for the short-term management of moderate to moderately severe pain ⁷. CAMBIA (diclofenac potassium for oral solution) is a prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ⁸.

For the fiscal year ended December 31, 2025, the company generated total revenues of $118.713 million ⁹, a decrease from $124.961 million in 2024 ¹⁰. Net product sales were $117.100 million ¹¹ in 2025, down from $120.849 million in 2024 ¹². Royalty revenue was $1.613 million ¹³ in 2025, compared to $2.012 million in 2024 ¹⁴. Other revenue was $0 million ¹⁵ in 2025, down from $2.100 million in 2024 ¹⁶. Cost of sales decreased to $35.383 million ¹⁷ in 2025 from $39.227 million ¹⁸ in 2024. Research and development expenses were $1.690 million ¹⁹ in 2025, a decrease from $3.822 million ²⁰ in 2024. Selling, general and administrative expenses were $69.000 million ²¹ in 2025, down from $75.051 million ²² in 2024. Amortization of intangible assets increased to $29.863 million ²³ in 2025 from $25.644 million ²⁴ in 2024. Impairment of intangible assets was $1.700 million ²⁵ in 2025, compared to $5.217 million ²⁶ in 2024. Restructuring charges were $2.889 million ²⁷ in 2025, up from $0.720 million ²⁸ in 2024. The company reported a net loss and comprehensive loss of $30.375 million ²⁹ in 2025, compared to $21.581 million ³⁰ in 2024. Basic and diluted net loss per share was $(4.74) ³¹ in 2025, compared to $(3.40) ³² in 2024. Cash and cash equivalents at year-end 2025 were $10.229 million ³³, a decrease from $50.588 million ³⁴ in 2024. Total long-term debt was $39.124 million ³⁵ in 2025, compared to $38.813 million ³⁶ in 2024.

Year-over-year, ROLVEDON net product sales increased by $8.1 million ³⁷ from $60.090 million ³⁸ in 2024 to $68.225 million ³⁹ in 2025, primarily due to higher volume and a $5.4 million ⁴⁰ adjustment of a prior period returns reserve, partially offset by lower net pricing. INDOCIN net product sales decreased by $7.9 million ⁴¹ from $26.761 million ⁴² in 2024 to $18.905 million ⁴³ in 2025 due to lower volume from generic competition. Sympazan net product sales increased by $0.9 million ⁴⁴ from $10.457 million ⁴⁵ in 2024 to $11.349 million ⁴⁶ in 2025, driven by higher volume. SPRIX net product sales increased by $0.3 million ⁴⁷ from $7.624 million ⁴⁸ in 2024 to $7.952 million ⁴⁹ in 2025, primarily due to favorable payor mix. Other net product sales decreased due to lower Otrexup sales as commercialization ceased in July 2025. Gross-to-net sales allowances on product sales increased by $50.8 million ⁵⁰ in 2025 compared to 2024, mainly due to higher ROLVEDON sales volumes and a shift in product mix towards ROLVEDON, which has a higher contractual rebate rate.

During 2025, the company completed several significant operational developments. On May 9, 2025, it divested Assertio Therapeutics, transferring all equity interests to ATIH Industries, LLC, which resulted in a net loss of $8.174 million ⁵¹ on the transaction ⁵². As a result, the company is no longer a defendant in any opioid-related litigation ⁵³. In July 2025, the company ceased commercialization of Otrexup, incurring $4.2 million ⁵⁴ in expenses, including inventory write-offs and a settlement accrual ⁵⁵. Key integration efforts were advanced in the third quarter of 2025 to consolidate operations and align products, including ROLVEDON, under Assertio Specialty ⁵⁶. This involved large purchases by national distributors to ensure consistent ROLVEDON supply during the integration, leading to no material net product sales of ROLVEDON in the fourth quarter of 2025 and anticipated similar results in the first quarter of 2026 ⁵⁷. On October 7, 2025, an amendment to the Manufacturing and Supply Agreement with Hanmi Pharmaceutical Co. Ltd. was entered into, fixing the price paid for the remaining term of the license agreement and amending payment timing for certain product royalties ⁵⁸. On December 26, 2025, a 1-for-15 reverse stock split was effected ⁵⁹.

The company anticipates that its existing cash, cash equivalents, and short-term investments, totaling $63.4 million ⁶⁰ at December 31, 2025, will be sufficient to fund operations and meet debt obligations for the next 12 months from the filing date ⁶¹. However, cash needs may vary due to factors such as reductions in net product sales and gross margin in the first quarter of 2026 due to the ROLVEDON transition, changes in working capital needs from large ROLVEDON purchases in Q3 2025, interest and principal payments on debt, and potential additional expenses from litigation ⁶².

The company expects sales of the newly labeled ROLVEDON to commence at a normal volume in the second quarter of 2026, following no material net product sales in the fourth quarter of 2025 and anticipated similar results in the first quarter of 2026 due to large purchases by national distributors in Q3 2025 to ensure consistent supply during integration into Assertio Specialty ⁶³. The company's future success is highly dependent on the commercial success of ROLVEDON, and any failure to grow or maintain its sales and profitability would materially and adversely impact the business ⁶⁴. The commercial success of ROLVEDON relies on factors such as successful execution of a commercial strategy focusing on clinics and hospitals, patient demand, recognition of same-day dosing trial results in National Comprehensive Cancer Network guidelines, coverage and reimbursement from third-party payors, consistent manufacturing and supply, compliance with regulatory requirements, differentiation from competing drugs, and intellectual property protection ⁶⁵.

The company expects INDOCIN net product sales to continue to decline in 2026 due to continued competition from existing generic entrants, as well as new and expected future generic entrants ⁶⁶. Royalty revenue from the CAMBIA licensing agreement is anticipated to be reduced to zero beginning in the third quarter of 2026, as the underlying patents expire in June 2026, leading to increased generic competition in Canada ⁶⁷.

The company expects that ongoing legal expenses will, and any settlements that it is able to negotiate may, continue to be a significant usage of cash in 2026 ⁶⁸. Cash flows from operating activities are expected to be reduced in the first quarter of 2026 due to the timing of cash collections and payments related to the large ROLVEDON purchases in Q3 2025, with an expected increase in cash flows from operating activities in the second quarter of 2026 ⁶⁹. The company's strategy is to focus on finding products that leverage existing capabilities to build an oncology portfolio, underpinned by talent, commercial capabilities, and a strong financial foundation ⁷⁰. It seeks to expand its portfolio through targeted acquisitions, including individual product acquisitions, commercialization agreements, licensing or technology agreements, and/or business combinations ⁷¹. The company primarily seeks assets that provide commercial synergies with current products, marketed products with significant remaining patent life or exclusivity, and products that are accretive to operating margins and cash flows in the near or medium term ⁷².

The company's principal material cash requirements consist of obligations related to payments for rebates, returns and discounts, payments for debt, non-cancelable leases for its office space, non-cancelable contractual obligations for purchase commitments, and cash payments for restructuring activities ⁷³. Total commitments to Jubilant HollisterStier LLC for SPRIX for 2026 and 2027 are approximately $2.0 million ⁷⁴. The company reached a settlement in principle with Antares in December 2025, requiring a payment of $1.2 million ⁷⁵ as of December 31, 2025, which would terminate the Antares Supply Agreement ⁷⁶. While there are no minimum purchase requirements for ROLVEDON under the amended Hanmi Agreement, if any orders are included in an annual forecasted purchase plan, at least 50% ⁷⁷ of such orders must be designated as binding ⁷⁸.

The company faces material risks including the potential inability to maintain attractive reimbursement for ROLVEDON through government programs like Medicare and Medicaid, and the risk of reduced coverage or reimbursement due to disputes over submitted Average Sales Price (ASP) data, which relies on assumptions that may be challenged ⁷⁹. There is a significant risk that the company may not successfully drive growth in ROLVEDON sales and profitability, especially if national distributors do not purchase historical volumes after the integration of ROLVEDON into Assertio Specialty ⁸⁰. Competition from generics has already adversely affected INDOCIN and CAMBIA sales, and the approval of additional generic or biosimilar versions of products, including ROLVEDON, could have further adverse effects ⁸¹. The company is dependent on single-source suppliers for active pharmaceutical ingredients and product manufacturing, and any supply disruptions or demands for higher prices could negatively impact sales and margins ⁸². Commercial disputes arising from collaboration and licensing arrangements, including those over intellectual property, could delay product commercialization and lead to costly litigation ⁸³. The pharmaceutical industry is intensely competitive, with many competitors having greater resources, and the company may be unable to compete successfully against other long-acting G-CSFs, opioids, anti-seizure medications, and migraine treatments ⁸⁴. Failure to negotiate acceptable pricing or obtain adequate reimbursement from third-party payors, or increased pressure to offer larger discounts, could adversely affect financial results ⁸⁵. Customer concentration, with three large national wholesale distributors representing the majority of revenues, poses a risk if any of these distributors fail to fulfill obligations, experience payment difficulties, or negotiate lower pricing ⁸⁶. Changes in laws and regulations, increased scrutiny, and investigations in the pharmaceutical industry, including potential U.S. federal government shutdowns, could impose additional costs and operational limitations ⁸⁷. The company may incur significant liability if found to be promoting "off-label" use of its products ⁸⁸. Healthcare reform initiatives, such as the Inflation Reduction Act of 2022 (IRA) and the Affordable Care Act (ACA), could reduce revenues, increase expenses, and adversely affect product commercialization through drug price negotiations, inflation rebates, and increased disclosure obligations ⁸⁹. Macroeconomic conditions, including inflationary pressures, high interest rates, and potential tariffs on imported pharmaceuticals, could increase business costs and negatively impact financial results ⁹⁰. The company's ability to protect its intellectual property is critical, and challenges to patents or claims of infringement by others could limit its ability to market products ⁹¹. The development of new drug candidates is inherently uncertain, and future product candidates may not receive regulatory approval or achieve market acceptance ⁹². The company relies on third-party contract research organizations for clinical trials, and their failure to perform could delay regulatory approvals ⁹³. The company is subject to risks associated with New Drug Applications (NDAs) submitted under Section 505(b)(2) of the FDCA, which can lead to significant delays and patent litigation ⁹⁴. The company's common stock may be delisted from The Nasdaq Capital Market if it fails to maintain compliance with listing standards, such as the minimum bid price of $1.00 ⁹⁵. The market price of the common stock has historically been volatile, and significant drops could lead to shareholder lawsuits ⁹⁶. Actions by activist shareholders, including proxy contests, could distract management and incur significant costs ⁹⁷. Unsolicited takeover attempts could also disrupt business operations ⁹⁸. Conversions of the 2027 Convertible Notes or future sales of common stock could lower the market price of the common stock and adversely impact the trading price of the notes ⁹⁹. The company's success is dependent on its executive management team, and changes could disrupt business and strategic relationships ¹⁰⁰. Despite its corporate structure, creditors of current or former operating subsidiaries could attempt to pierce the corporate veil, adversely affecting the company's assets ¹⁰¹. Failure to satisfy regulatory requirements for internal controls could harm the stock price ¹⁰². Business interruptions from natural disasters or other emergencies could severely disrupt operations ¹⁰³. Data breaches and cyber-attacks could result in information theft, data corruption, and significant business disruption ¹⁰⁴. The use of new technologies like AI and ML may pose security and other risks to sensitive data, potentially leading to reputational harm and liability ¹⁰⁵.

Management emphasizes a focus on supporting patients by marketing differentiated products primarily in the oncology market, with ROLVEDON as the lead product ¹⁰⁶. The company's business strategy is talent-driven and underpinned by proven commercial capabilities and a strong financial foundation, aiming to attract and retain top talent, maximize product impact and reach through its commercial organization, and leverage its financial position for long-term growth and strategic acquisitions ¹⁰⁷. Management plans to continue vigorously defending itself in legal matters and seeking efficient, cost-effective resolutions ¹⁰⁸. For the upcoming period, management anticipates that existing cash, cash equivalents, and short-term investments of $63.4 million ¹⁰⁹ as of December 31, 2025, will be sufficient to fund operations and meet debt obligations for the next 12 months ¹¹⁰. Sales of the newly labeled ROLVEDON are expected to commence at a normal volume in the second quarter of 2026, following no material net product sales in the fourth quarter of 2025 and anticipated similar results in the first quarter of 2026 ¹¹¹. Management expects ongoing legal expenses and potential settlement payments to be a significant usage of cash in 2026 ¹¹².